$CLYM

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 1

Climb Bio (CLYM) and Mabworks presented Phase 1 data for CLYM116/MIL116, an IgA nephropathy drug, at Kidney Week 2026. Trials in Australia and China showed sustained APRIL suppression and tolerability. Phase 2 trial is enrolling, with data expected in 2027.

Climb Bio (CLYM) will present Phase 2 data for Budoprutug in treating primary membranous nephropathy at ASN Kidney Week 2026 on October 24. The study could show the drug's effectiveness in this rare kidney disease.

Climb Bio (CLYM) shares rose 10% after Deutsche Bank initiated coverage with a Buy rating and $28 price target, citing its autoimmune pipeline and attractive valuation. Analyst David Hoang highlighted CLYM116 as a key growth driver and noted upcoming clinical updates as catalysts. The firm sees significant commercial potential in the company's pipeline, including budoprutug for multiple B cell-mediated disorders.

H.C. Wainwright reiterated a Buy rating and $30 price target for Climb Bio (CLYM) ahead of clinical data presentations. The stock has risen 511% in the past year, trading at $11. Analysts expect data on CLYM116 and budoprutug for kidney diseases at a 2026 conference. Multiple analysts have raised price targets, citing positive Phase 1 and 2 results.

Raymond James maintained a Strong Buy rating and $34.00 price target for Climb Bio (NASDAQ:CLYM) after Phase 2 budoprutug data abstract release. The stock is up 453% over a year, trading at $10.94. Analysts' targets range from $18 to $40, with a consensus Strong Buy. Initial data shows safety and B cell depletion, with a full presentation expected on October 24. Recent Phase 1 trial results for CLYM116 also led to multiple analyst upgrades and higher price targets.

Climb Bio (NASDAQ:CLYM) will present Phase 2 data for its kidney disease therapies, CLYM116 and budoprutug, at the American Society of Nephrology Kidney Week 2026. Budoprutug, with FDA designations, is in trials for multiple conditions, while CLYM116 targets IgA nephropathy.

Raymond James updated its Healthcare Top Picks for October, adding Xencor (XNCR), Calyxt (CLYM), and UnitedHealth Group (UNH), while removing Relay Therapeutics, Tyra Biosciences, and Oscar Health. The firm cited near-term catalysts for Xencor and Calyxt, and expects strong earnings from UnitedHealth.

Thomas Stephen Basil sold 100,000 shares of Climb Bio, Inc. (CLYM) at $13.67 ($1.37M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Climb Bio (CLYM) stock fell 7% to $14.00 in pre-market trading after releasing Phase 1 clinical data for CLYM116, showing near-complete APRIL protein suppression and sustained IgA reductions. The decline follows a 'buy the rumor, sell the news' pattern, with investors taking profits after the data release. The company's Phase 2 trial data is not expected until 2027, contributing to the pullback. The broader market showed modest gains, with the S&P 500, Dow Jones, and Nasdaq up 0.3%, 0.6%, and 0.